Judith Absalon

TL;DR: The ability of MenB-FHbp to provide broad coverage against MenB strains expressing diverse FHbp variants is supported, with percentages of subjects with protective responses to as many as 8 strains combined (4 primary plus additional strains).

TL;DR: Different contexts in which a 2- or 3-dose primary vaccination schedule might be preferred (eg, routine prospective vaccination vs outbreak control) are reviewed.

TL;DR: In this paper, the authors evaluated immunopersistence through 26 months following MenB-FHBP boosting after 2 or 3 primary doses in adolescents and found that the meningococcal serogroup B (MenB) vaccine was well tolerated, with ≤ 12.5% of subjects reporting adverse events (AEs) and local and systemic reactions.

TL;DR: An extensive clinical development program showed that the meningococcal serogroup B-factor H binding protein (MenB-FHbp) vaccine affords protection against MenB disease for adolescents and adults, and data suggested no clinically meaningful differences when administered as a three-dose schedule based on sex, ages assessed, or races evaluated.

TL;DR: A step-wise approach to evaluate and quantify obstetric and maternal risk factors in pregnancy based on review of published literature and guidelines is developed and critically assessed these factors in the context of designing inclusion and exclusion criteria for maternal vaccine studies.